JN

Janis Naeve

Partner at Cota Capital

San Francisco, California

Overview

Work Experience

  • Partner

    2022 - Current

  • Advisory Board Member

    2024

    AI-SDM is newly formed an interdisciplinary research institute funded by NSF to harness the power of AI and social sciences to empower decision-makers with tools that augment human judgment in complex, time-sensitive situations. AI-SDM at CMU collaborates with a diverse network of partners, including academic institutions, government agencies, and non-profit organizations, to develop and deploy impactful solutions that account for risk, trust, and equity in decision-making.

  • Board Observer

    2022

    Excision BioTherapeutics, Inc. is a clinical-stage biotechnology company developing CRISPR-based therapies as potential cures for viral infectious diseases.

  • Board Member

    2022

    Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomic analysis for precision medicine, providing advanced tools and analytics for cell and gene therapies.

  • Board Member

    2022

    Algen, spun out of Jennifer Doudn'as lab is a platform therapeutics and drug discovery company using the world’s leading CRISPR and AI to uncover disease-driving RNA messages to find treatments for cancer, inflammation and other diseases.

  • Board Member

    2022

    Probius, spun out of Stanford, is a deep-tech company bridging the data gap between biology and AI by combining physics, mathematics, and biological data into their bioanalytical platform, Quantum Electrochemical Spectroscopy (QES) which translates a sample aliquot into a high-dimensional phenotypic signature, a digital twin, that can be re-analyzed and redefined in the cloud.

  • Board Observer

    2022

    CellFE has developed a scalable, high throughput microfluidic device for the efficient delivery of gene-editing molecules into cells enabling cell and gene therapies.

  • Board Member

    2022 - 2023

    Miroculus applied microfluidics in designing intuitive and flexible platforms based on its patented technology, simplifying complicated Next Generation sequencing protocols. Company was acquired by Integra Biosciences in March 2023

  • KidneyX Steering Committee

    2022 - 2022

  • The Fund@Caltech Advisory Committee

    2020 - 2022

Relevant Websites